在患有尿道炎的患者中,免疫抑制治疗的坚持障碍
Karen Sun1, Rayna Marshall2, Michael Frankland3
1Department of Medicine, Georgetown School of Medicine, Washington, District of Columbia, USA.
Ocular immunology and inflammation
|November 26, 2024
概括
膜炎患者的免疫调节疗法 (IMT) 坚持障碍包括药物成本,施用难度和调度挑战. 解决这些问题可以改善治疗坚持和患者的结果.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尿道炎是一组需要长期治疗的炎症性眼病.
- 免疫调节疗法 (IMT) 对于治疗紫外线炎至关重要,但坚持治疗可能具有挑战性.
研究的目的:
- 为了确定在美国乌维炎患者中免疫调节疗法 (IMT) 坚持的障碍.
- 为改善患者坚持治疗的策略提供信息,并改善脑膜炎管理中的临床结果.
主要方法:
- 从2021年9月到2022年8月进行了一项多中心调查.
- 98名患有眼部炎症疾病的成人和儿科患者接受IMT,完成了自我报告调查.
- 调查评估了与药物管理,调度和监测相关的挑战.
主要成果:
- 近一半的患者 (52%) 需要提醒服用药物,20%的人发现定期服用药物很困难.
- 12%的人在多次每日剂量方面遇到了困难,15%的人因缺乏补充而错过了剂量.
- 监测实验室研究的障碍包括时间 (10%) 和成本 (22%).
结论:
- 关键的IMT遵守障碍包括药物成本,管理复杂性和遵守时间表.
- 应对这些挑战对于改善皮膜炎患者的IMT坚持是必不可少的.
- 加强坚持可以导致更好的脑膜炎管理和改善临床结果.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Pulmonary Tuberculosis I
220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Open Angle Glaucoma: Treatment
393
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
393
Cell-mediated Immune Responses
67.1K
Overview
67.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113


